Skelaxin is owned by King Pharms.
Skelaxin contains Metaxalone.
Skelaxin has a total of 1 drug patent out of which 0 drug patents have expired.
Skelaxin was authorised for market use on 30 August, 2002.
Skelaxin is available in tablet;oral dosage forms.
Skelaxin can be used as treatment of musculoskeletal conditions.
The generics of Skelaxin are possible to be released after 06 February, 2026.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7122566||KING PHARMS||Metaxalone products, method of manufacture, and method of use|| |
(3 years from now)
Market Authorisation Date: 30 August, 2002
Treatment: Treatment of musculoskeletal conditions
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic